| ￥3000 | |
| Z05824-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 81.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 100-115 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in PBS, 500mM Nacl (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Siglec-4a, also known as Myelin-Associated Glycoprotein (MAG), is a type I transmembrane glycoprotein belonging to the Siglec family, a subgroup of the Ig superfamily. Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid-containing gangliosides and to the glycoproteins RTN4R and RTN4RL2. |
| Synonyms | MAG; Siglec4a; Siglec-4a; S-MAG; GMA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
